GlassScriptPhysician profile
Jennifer Bennett
NPI 1932255411
$7,550.62
in general payments reported to CMS, 2019-2025
27 companies · $17.76 in 2025
The $17.76 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $629 · 2020: $242 · 2021: $1,139 · 2022: $4,867 · 2023: $400 · 2024: $257 · 2025: $17.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $674.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $674.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $4,298.14 | 2020-2023 | Axonics |
| Baxter Healthcare | $1,480.00 | 2022 | |
| Astellas Pharma US INC | $239.15 | 2019-2023 | Xtandi, Myrbetriq |
| Abbvie INC. | $239.01 | 2022-2024 | Botox |
| Urogen Pharma, INC. | $178.53 | 2021-2024 | |
| Neotract INC. | $144.18 | 2019 | |
| Medtronic USA, INC. | $134.77 | 2019 | |
| Teleflex LLC | $127.80 | 2021 | |
| Inari Medical, INC. | $118.77 | 2022 | |
| Procept Biorobotics Corporation | $82.05 | 2019 | |
| Sagent Pharmaceuticals | $70.15 | 2019 | |
| Urovant Sciences INC | $46.69 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $45.80 | 2019 | |
| Coloplast Corp | $42.55 | 2019-2022 | |
| Rochester Medical Corporation | $38.12 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $37.21 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $29.22 | 2024 | Tagrisso |
| Regeneron Healthcare Solutions, INC. | $26.84 | 2024 | Libtayo |
| Pfizer INC. | $25.98 | 2020 | |
| Myovant Sciences INC. | $20.50 | 2022 | |
| Genzyme Corporation | $20.24 | 2023 | |
| Ambu INC. | $20.10 | 2022 | |
| Myriad Genetic Laboratories, INC. | $18.50 | 2022 | |
| Antares Pharma, INC. | $18.21 | 2022 | |
| Endo USA, INC. | $17.76 | 2025 | Xiaflex |
| Janssen Biotech, INC. | $15.25 | 2022 | |
| Sumitomo Pharma America, INC. | $15.10 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.